The biopharmaceutical company HUTCHMED announces data from several studies of its compounds, including savolitinib, fruquintinib and surufatinib, to be presented at the upcoming AACR Annual Meeting 2025.
The biopharmaceutical company has completed enrollment for a Phase II study evaluating its drug savolitinib in treating gastric cancer patients with MET amplification.
The biopharmaceutical company has released its 2024 Annual Report and announced the details of its upcoming Annual General Meeting.
The biopharmaceutical company receives conditional approval from China's NMPA for its TAZVERIK® treatment for relapsed or refractory follicular lymphoma, marking an important milestone in expanding its product portfolio.
The healthcare company announces the retirement of two long-serving independent directors from its board.
The biopharmaceutical company presents new data on its cancer drug candidates at a medical conference.
The biopharmaceutical company has published its annual Form 20-F filing.
The biopharmaceutical firm reported a 25% decrease in total revenue and a significant drop in net income for 2024, despite growth in oncology product sales and achieving profitability ahead of schedule. The company faces challenges in maintaining growth and profitability in a competitive market.
The biopharmaceutical company announces positive results from a Phase II/III study of its cancer drug combination for advanced renal cell carcinoma.
The biopharmaceutical company has adopted a new long-term incentive plan for its employees, effective from April 2025.